Ultra-rapid insulin shows promise in phase 3 trial for type 1 diabetes - PharmaTimes BioChaperone Lispro demonstrates improved post-meal glucose control compared to Humalog

#Ultrarapidinsulin #phase3trial #type1diabetes #BioChaperoneLispro #THDB0206injection #postmealglucosecontrol #TonghuaDongbao #phase3clinicaltrial #ultrarapidinsulinformulation #HbA1creduction #bloodglucose #selfmonitoringbloodglucose #SMBG #diabetes #obesity
zurl.co/nlXjK